NCT06228677Recruiting
Comparison of Catecholamine Concentrations in Venous Blood During Selective Adrenal Artery Embolization
Comparison of Catecholamine Concentrations in Adrenal Venous Blood and Peripheral Venous Blood During Percutaneous Selective Adrenal Artery Embolization in Hypertensive Patients With Primary Aldosteronism: A Prospective Cohort Study
Source: ClinicalTrials.gov · Last updated 29 Jan 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
To explore the relationship between perioperative blood pressure and catecholamine concentrations in adrenal venous blood and peripheral venous blood in hypertensive patients with primary aldosteronism (PA) who underwent percutaneous selective adrenal artery embolization (SAAE). In order to elucidate the related phenomena and possible mechanisms of blood pressure fluctuations caused by SAAE treatment in hypertensive patients with PA.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 196 (estimated)
- First submitted
- 19 Jan 2024
- Start date
- 18 Sept 2023
- Primary completion date
- 30 Jun 2026
- Lead sponsor
- First Affiliated Hospital of Chengdu Medical College
- Diseases
- High blood pressure
- NCT number
- NCT06228677
What you commit to
- Study type: Observational
- Planned participants: 196
- From 18 Sept 2023 to the primary completion date, 30 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients diagnosed with primary hypertension or secondary hypertension attributed to other etiologies.
- Presence of significant systemic diseases, with particular attention to hepatic and renal dysfunction.
- Pronounced allergic reaction to contrast agents.
- Any other serious systemic diseases with a life expectancy of less than 12 months.
Other
- Female participants who are presently pregnant, lactating, or with intentions to conceive within the forthcoming year.
- Participants concurrently enrolled or expressing interest to participate in other clinical trials, the outcomes of which could potentially influence the results of the current study.
- The researcher's discretion deems the subject inappropriate for inclusion in the study for any given reason.
Who the study is looking for
- Age ≥18 years with no gender restrictions.
- Adherence to the "Primary Aldosteronism" Diagnosis and Treatment Guidelines, confirmed diagnosis of primary aldosteronism following rigorous drug washout, and identification as either aldosteronoma or idiopathic aldosteronism via adrenal vein blood sampling.
- Blood pressure metrics that satisfy any of the subsequent conditions: a) Clinic-recorded blood pressure ≥140/90mmHg; b) 24-hour ambulatory blood pressure monitoring results displaying average blood pressure \>130/80 mmHg or daytime readings \>135/85 mmHg.
- Adrenal CT scan revealing adrenal hyperplasia, nodular formations, or no significant morphological deviations.
- Hypertension history surpassing a duration of 6 months.
- Prior to screening, patients or their lawful guardians must provide a signed informed consent, sanctioned by the ethics committee.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated Hospital of Chengdu Medical College Coordinator of this site? Confirm its status | Chengdu | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.